Salsalate: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>David Finn No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[pharmacology]], '''salsalate''', also called '''salicylsalicylic acid''' and '''disalicylic acid''', is a [[medication]] which is a [[non-steroidal anti-inflammatory agent]]. Salsalate is related to acetylsalicylic acid ([[aspirin]]), but unlike acetylsalicylic acid, salsalate does not irreversibly inhibit [[cyclooxygenase]] and thus is not an [[anti-platelet agent]]. | In [[pharmacology]], '''salsalate''', also called '''salicylsalicylic acid''' and '''disalicylic acid''', is a [[medication]] which is a [[non-steroidal anti-inflammatory agent]]. Salsalate is related to acetylsalicylic acid ([[aspirin]]), but unlike acetylsalicylic acid, salsalate does not irreversibly inhibit [[cyclooxygenase]] and thus is not an [[anti-platelet agent]]. | ||
Revision as of 12:15, 22 November 2011
In pharmacology, salsalate, also called salicylsalicylic acid and disalicylic acid, is a medication which is a non-steroidal anti-inflammatory agent. Salsalate is related to acetylsalicylic acid (aspirin), but unlike acetylsalicylic acid, salsalate does not irreversibly inhibit cyclooxygenase and thus is not an anti-platelet agent.
Salsalate may reduce the Glycosylated hemoglobin A1c in patients with diabetes mellitus type 2.[1]
Drug toxicity
Tinnitus may happen, but is unlikely if the total daily dose is 3 grams or less.[1]
Gastrointestinal toxicity is less than with other non-steroidal anti-inflammatory agents.[2][3]
References
- ↑ 1.0 1.1 Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE et al. (2010). "The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.". Ann Intern Med 152 (6): 346-57. DOI:10.1059/0003-4819-152-6-201003160-00004. PMID 20231565. Research Blogging.
Cite error: Invalid
<ref>tag; name "pmid20231565" defined multiple times with different content - ↑ Roth S, Bennett R, Caldron P, Hartman R, Mitchell C, Doucette M et al. (1990). "Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study.". Semin Arthritis Rheum 19 (4 Suppl 2): 11-9. PMID 2181673. [e]
- ↑ Lanza F, Rack MF, Doucette M, Ekholm B, Goldlust B, Wilson R (1989). "An endoscopic comparison of the gastroduodenal injury seen with salsalate and naproxen.". J Rheumatol 16 (12): 1570-4. PMID 2625689. [e]